Alnylam: Q3 Earnings Snapshot

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported third-quarter net income of $147.8 million, after reporting a loss in the same period a year earlier.

On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of $1.15.

The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.61 per share.

The RNA interference drug developer posted revenue of $750.5 million in the period, also exceeding Street forecasts. Eleven analysts surveyed by Zacks expected $406.1 million.

Alnylam shares have declined 34% since the beginning of the year. The stock has dropped 26% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY